You can find many anecdotal stories about how Cannabidiol (CBD) has helped someone with pain, anxiety, etc. There are some studies being done about the effectiveness of CBD. Following are topics and the research that been done on those topics.
We are presenting the following chart for your information. In no way is this information meant as a substitute for or alternative to information from health care practitioners.
| ADD / ADHD | Impact of ADHD and Cannabis Use on Executive Functioning in Young Adults |
| Addiction | Cannabidiol for the Treatment of Cannabis Withdrawal Syndrome: A Case Report |
| Addiction | Cannabidiol Reduces Cigarette Consumption in Tobacco Smokers: Preliminary Findings |
| Alzheimers | Cannabinoids for the Treatment of Dementia |
| Anxiety | Plant-based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies With Supporting Preclinical Evidence |
| Arthritis | Preliminary Assessment of the Efficacy, Tolerability and Safety of a Cannabis-Based Medicine (Sativex) in the Treatment of Pain Caused by Rheumatoid Arthritis |
| Asthma | The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke |
| Autism | Endocannabinoid Signaling in Autism |
| Autism | A Novel Approach to the Symptomatic Treatment of Autism |
| Cancer | Cannabidiol as potential anticancer drug |
| Cancer | The Inhibitory Effects of Cannabidiol on Systemic Malignant Tumors |
| Colitis & Crohn’s | Cannabis Finds Its Way Into Treatment of Crohn’s Disease |
| Depression | Antidepressant-like Effect of delta9-tetrahydrocannabinol and Other Cannabinoids Isolated From Cannabis Sativa L |
| Depression | The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants |
| Diabetes | The Endocannabinoid System in Obesity and Type 2 Diabetes |
| Diabetes | The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications |
| Epilepsy | Cannabidiol: Promise and Pitfalls |
| Epilepsy | The Cannabinoids as Potential Antiepileptics |
| Heart Disease | Cannabidiol, a Nonpsychoactive Cannabis Constituent, Protects Against Myocardial Ischemic Reperfusion Injury |
| Heart Disease | Is the Cardiovascular System a Therapeutic Target for Cannabidiol? |
| Huntington’s | Prospects for Cannabinoid Therapies in Basal Ganglia Disorders |
| Inflammation | Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress |
| Inflammation | Cannabidiol Reduces Intestinal Inflammation Through the Control of Neuroimmune Axis |
| Kidney Disease | Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death |
| Liver Disease | The Endocannabinoid System and Liver Diseases |
| Liver Disease | Cannabidiol Causes Activated Hepatic Stellate Cell Death Through a Mechanism of Endoplasmic Reticulum Stress-Induced Apoptosis |
| Migraine | Cannabinoids and Hallucinogens for Headache |
| Migraine | The Endocannabinoid System and Migraine |
| Mood Disorders | The Endocannabinoid System and Psychiatric Disorders |
| Mood Disorders | The Endocannabinoid System and the Treatment of Mood and Anxiety Disorders |
| Mood Disorders | Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow |
| Multiple Sclerosis | Meta-analysis of Cannabis Based Treatments for Neuropathic and Multiple Sclerosis-Related Pain |
| Multiple Sclerosis | Oromucosal delta9-tetrahydrocannabinol/cannabidiol for Neuropathic Pain Associated With Multiple Sclerosis: An Uncontrolled, Open-Label, 2-year Extension Trial |
| Nausea | Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus |
| Nausea | Regulation of Nausea and Vomiting by Cannabinoids and the Endocannabinoid System |
| Nausea | Regulation of Nausea and Vomiting by Cannabinoids |
| Nausea | Preliminary Efficacy and Safety of an Oromucosal Standardized Cannabis Extract in Chemotherapy-Induced Nausea and Vomiting |
| Pain | Pot Users Less Likely to Take Painkillers |
| Pain | Cannabinoids Suppress Inflammatory and Neuropathic Pain by Targeting α3 Glycine Receptors |
| Pain | Cannabinoids in the Management of Difficult to Treat Pain |
| Parkinsons | Prospects for Cannabinoid Therapies in Basal Ganglia Disorders |
| PTSD | Cannabinoid Modulation of Fear Extinction Brain Circuits: A Novel Target to Advance Anxiety Treatmen |
| PTSD | Reductions in Circulating Endocannabinoid Levels in Individuals With Post-Traumatic Stress Disorder Following Exposure to the World Trade Center Attacks |
| Schizophrenia | Cannabis Drug Shows Promise in Treating Schizophrenia |
| Schizophrenia | Cannabidiol, a Cannabis Sativa Constituent, as an Antipsychotic Drug |
| Skin Conditions | Endocannabinoids Modulate Human Epidermal Keratinocyte Proliferation and Survival via the Sequential Engagement of Cannabinoid receptor-1 and Transient Receptor Potential vanilloid-1 |
| Skin Conditions | Cannabidiol Exerts Sebostatic and Antiinflammatory Effects on Human Sebocytes |
| Sleep Disorders | Endocannabinoid Modulation of Cortical Up-States and NREM Sleep |
| Sleep Disorders | The Nonpsychoactive Cannabis Constituent Cannabidiol Is a Wake-Inducing Agent |
| Stress | Endocannabinoids and stress |
| Stress | Low-frequency Stimulation Evokes Serotonin Release in the Nucleus Accumbens and Induces Long-Term Depression via Production of Endocannabinoid |
| Stroke | Cannabis and Cannabinoid Biology in Stroke: Controversies, Risks, and Promises |
| TBI | Cannabidiol, a Nonpsychoactive Cannabis Constituent, Protects Against Myocardial Ischemic Reperfusion Injury |
